Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Tanriover, Mine; Doganay, Hamdi; AKOVA, MURAT; GÜNER, HATİCE; Azap, Alpay; AKHAN, SILA; Kose, Sukran; Erdinc, Fatma; AKALIN, EMİN; Tabak, Omer; Pullukcu, Husnu; Batum, Ozgur; Yavuz, Serap; Turhan, Ozge; Yildirmak, Mustafa; Koksal, Iftihar; Tasova, Yesim; Korten, Volkan; YILMAZ, GÜRDAL; Celen, Mustafa; Altin, Sedat; Celik, Ilhami; Bayindir, Yasar; Karaoglan, Ilkay; Yilmaz, Aydin; Ozkul, Aykut; Gur, Hazal; Unal, Serhat

doi:10.1016/s0140-6736(21)01429-x

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Copy For Citation

Tanriover M. D., Doganay H. L., AKOVA M., GÜNER H. R., Azap A., AKHAN S., ...More

LANCET, vol.398, no.10296, pp.213-222, 2021 (SCI-Expanded)

Publication Type: Article / Article
Volume: 398 Issue: 10296
Publication Date: 2021
Doi Number: 10.1016/s0140-6736(21)01429-x
Journal Name: LANCET
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Psycinfo, Veterinary Science Database
Page Numbers: pp.213-222
Karadeniz Technical University Affiliated: Yes

Abstract

Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey.